Literature DB >> 3004275

An overnight high-dose dexamethasone suppression test for rapid differential diagnosis of Cushing's syndrome.

J B Tyrrell, J W Findling, D C Aron, P A Fitzgerald, P H Forsham.   

Abstract

We have developed a high-dose dexamethasone suppression test that can be administered overnight with a single 8-mg dose and used the new procedure in the differential diagnosis of 83 patients with Cushing's syndrome. In 76 patients with surgically or pathologically proven cause--60 with Cushing's disease, 7 with the ectopic adrenocorticotrophic hormone syndrome, and 9 with adrenal tumors--suppression of plasma cortisol levels to less than 50% of baseline indicated a diagnosis of Cushing's disease. The test had a sensitivity of 92%, a specificity of 100%, and a diagnostic accuracy of 93%. These values equal or exceed those of the standard 2-day test whether based on suppression of urinary 17-hydroxycorticosteroids or plasma cortisol. We conclude that this overnight, high-dose dexamethasone suppression test is practical and reliable in the differential diagnosis of Cushing's syndrome.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3004275     DOI: 10.7326/0003-4819-104-2-180

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  15 in total

Review 1.  Cushing's syndrome in children and adolescents: current diagnostic and therapeutic strategies.

Authors:  M A Magiakou; G P Chrousos
Journal:  J Endocrinol Invest       Date:  2002-02       Impact factor: 4.256

2.  Persistent hypokalemia after successful adrenalectomy in a patient with Cushing's syndrome due to ectopic ACTH secretion: possible role of 11beta-hydroxysteroid dehydrogenase inhibition.

Authors:  E Arteaga; C Fardella; C Campusano; I Cárdenas; P Martinez
Journal:  J Endocrinol Invest       Date:  1999-12       Impact factor: 4.256

3.  Limbic dysregulation is associated with lowered heart rate variability and increased trait anxiety in healthy adults.

Authors:  Lilianne R Mujica-Parodi; Mayuresh Korgaonkar; Bosky Ravindranath; Tsafrir Greenberg; Dardo Tomasi; Mark Wagshul; Babak Ardekani; David Guilfoyle; Shilpi Khan; Yuru Zhong; Ki Chon; Dolores Malaspina
Journal:  Hum Brain Mapp       Date:  2009-01       Impact factor: 5.038

Review 4.  Dynamic testing in Cushing's syndrome.

Authors:  Blerina Kola; Ashley B Grossman
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

5.  Glucocorticoid-Induced Metabolic Disturbances Are Exacerbated in Obese Male Mice.

Authors:  Innocence Harvey; Erin J Stephenson; JeAnna R Redd; Quynh T Tran; Irit Hochberg; Nathan Qi; Dave Bridges
Journal:  Endocrinology       Date:  2018-06-01       Impact factor: 4.736

Review 6.  Medical management of pituitary adenomas: the special case of management of the pregnant woman.

Authors:  Marcello Delano Bronstein; Luiz Roberto Salgado; Nina Rosa de Castro Musolino
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

7.  Cost-effectiveness and accuracy of the tests used in the differential diagnosis of Cushing's syndrome.

Authors:  J Puig; A Wägner; A Caballero; J Rodríguez-Espinosa; S M Webb
Journal:  Pituitary       Date:  1999       Impact factor: 4.107

8.  Clinical laboratory findings and results of therapy in 55 patients with Cushing's syndrome.

Authors:  C Erem; E Algün; N Ozbey; A Azezli; F Aral; Y Orhan; S Molvalilar; E Sencer
Journal:  J Endocrinol Invest       Date:  2003-01       Impact factor: 4.256

9.  Corticotropin-releasing hormone production by a small cell carcinoma in a patient with ACTH-dependent Cushing's syndrome.

Authors:  R J Auchus; G Mastorakos; T C Friedman; G P Chrousos
Journal:  J Endocrinol Invest       Date:  1994-06       Impact factor: 4.256

10.  The role of non-invasive dynamic tests in the diagnosis of Cushing's syndrome.

Authors:  L Vilar; M C Freitas; L A Naves; V Canadas; J L Albuquerque; C A Botelho; C S Egito; M J Arruda; L M Silva; C M Arahata; R Agra; L H C Lima; M Azevedo; L A Casulari
Journal:  J Endocrinol Invest       Date:  2008-11       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.